Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme
To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster). The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey co...
Gespeichert in:
| Veröffentlicht in: | Arab Journal of Urology 2022-01, Vol.20 (1), p.14-23 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 1 |
| container_start_page | 14 |
| container_title | Arab Journal of Urology |
| container_volume | 20 |
| creator | Noweir, Amr Abusamra, Ashraf Al Zarooni, Abdelqader Binbay, Murat Doble, Adam Tariq, Luqman Aziz, Fayaz El Hasnaoui, Abdelkader |
| description | To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster).
The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L).
In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3-15.4%) in Turkey, to 23.76% (95% CI 21.8-25.6%) in Egypt, and 23.79% (95% CI 21.2-26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%; |
| doi_str_mv | 10.1080/2090598X.2021.2010451 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8881068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35223105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-17d7586a5778b2620d2e4f5b90ceca72414a5e6fcc19becac987fbfeb3e67d103</originalsourceid><addsrcrecordid>eNpVkdtKxDAQhoMoKus-gpIXqCZp06ZeCLJ4gtVdPIB3IU2n3UCblqRd8DF8Y1v2wHqTCTPzfzPMj9AlJdeUCHLDSEp4Kr6vGWF0eCiJOD1C52M-GAvHB_8zNPXeZCSKkpAQEZ-is5AzFlLCz9Hv0sFaVWA14KbAGVhTWty6xneqMxqvflpwbaW8UVjVjS1xtwKs8r7qcAkWnKpw27R9NXQ3dkQUZg341eR5BfhB-Q6cxbOmt50z4G_xO_hB68fOkfTxdr_8eF58jiNLp-oaLtBJoSoP022coK_Hh8_ZczBfPL3M7ueBjmLRBTTJEy5ixZNEZCxmJGcQFTxLiQatEhbRSHGIC61pmg0ZnYqkyArIQoiTnJJwgu423LbPasg1DBuqSrbO1Mr9yEYZ-b9izUqWzVoKISiJxQDgG4AeruUdFHstJXK0Se5skqNNcmvToLs6HLxX7UwJ_wBaIZK7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Noweir, Amr ; Abusamra, Ashraf ; Al Zarooni, Abdelqader ; Binbay, Murat ; Doble, Adam ; Tariq, Luqman ; Aziz, Fayaz ; El Hasnaoui, Abdelkader</creator><creatorcontrib>Noweir, Amr ; Abusamra, Ashraf ; Al Zarooni, Abdelqader ; Binbay, Murat ; Doble, Adam ; Tariq, Luqman ; Aziz, Fayaz ; El Hasnaoui, Abdelkader</creatorcontrib><description>To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster).
The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L).
In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3-15.4%) in Turkey, to 23.76% (95% CI 21.8-25.6%) in Egypt, and 23.79% (95% CI 21.2-26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%;
< 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (
< 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (
< 0.001).
The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.</description><identifier>ISSN: 2090-598X</identifier><identifier>EISSN: 2090-598X</identifier><identifier>EISSN: 2090-5998</identifier><identifier>DOI: 10.1080/2090598X.2021.2010451</identifier><identifier>PMID: 35223105</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><ispartof>Arab Journal of Urology, 2022-01, Vol.20 (1), p.14-23</ispartof><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.</rights><rights>2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-17d7586a5778b2620d2e4f5b90ceca72414a5e6fcc19becac987fbfeb3e67d103</citedby><cites>FETCH-LOGICAL-c468t-17d7586a5778b2620d2e4f5b90ceca72414a5e6fcc19becac987fbfeb3e67d103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881068/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881068/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35223105$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noweir, Amr</creatorcontrib><creatorcontrib>Abusamra, Ashraf</creatorcontrib><creatorcontrib>Al Zarooni, Abdelqader</creatorcontrib><creatorcontrib>Binbay, Murat</creatorcontrib><creatorcontrib>Doble, Adam</creatorcontrib><creatorcontrib>Tariq, Luqman</creatorcontrib><creatorcontrib>Aziz, Fayaz</creatorcontrib><creatorcontrib>El Hasnaoui, Abdelkader</creatorcontrib><title>Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme</title><title>Arab Journal of Urology</title><addtitle>Arab J Urol</addtitle><description>To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster).
The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L).
In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3-15.4%) in Turkey, to 23.76% (95% CI 21.8-25.6%) in Egypt, and 23.79% (95% CI 21.2-26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%;
< 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (
< 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (
< 0.001).
The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.</description><issn>2090-598X</issn><issn>2090-598X</issn><issn>2090-5998</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkdtKxDAQhoMoKus-gpIXqCZp06ZeCLJ4gtVdPIB3IU2n3UCblqRd8DF8Y1v2wHqTCTPzfzPMj9AlJdeUCHLDSEp4Kr6vGWF0eCiJOD1C52M-GAvHB_8zNPXeZCSKkpAQEZ-is5AzFlLCz9Hv0sFaVWA14KbAGVhTWty6xneqMxqvflpwbaW8UVjVjS1xtwKs8r7qcAkWnKpw27R9NXQ3dkQUZg341eR5BfhB-Q6cxbOmt50z4G_xO_hB68fOkfTxdr_8eF58jiNLp-oaLtBJoSoP022coK_Hh8_ZczBfPL3M7ueBjmLRBTTJEy5ixZNEZCxmJGcQFTxLiQatEhbRSHGIC61pmg0ZnYqkyArIQoiTnJJwgu423LbPasg1DBuqSrbO1Mr9yEYZ-b9izUqWzVoKISiJxQDgG4AeruUdFHstJXK0Se5skqNNcmvToLs6HLxX7UwJ_wBaIZK7</recordid><startdate>20220102</startdate><enddate>20220102</enddate><creator>Noweir, Amr</creator><creator>Abusamra, Ashraf</creator><creator>Al Zarooni, Abdelqader</creator><creator>Binbay, Murat</creator><creator>Doble, Adam</creator><creator>Tariq, Luqman</creator><creator>Aziz, Fayaz</creator><creator>El Hasnaoui, Abdelkader</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220102</creationdate><title>Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme</title><author>Noweir, Amr ; Abusamra, Ashraf ; Al Zarooni, Abdelqader ; Binbay, Murat ; Doble, Adam ; Tariq, Luqman ; Aziz, Fayaz ; El Hasnaoui, Abdelkader</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-17d7586a5778b2620d2e4f5b90ceca72414a5e6fcc19becac987fbfeb3e67d103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noweir, Amr</creatorcontrib><creatorcontrib>Abusamra, Ashraf</creatorcontrib><creatorcontrib>Al Zarooni, Abdelqader</creatorcontrib><creatorcontrib>Binbay, Murat</creatorcontrib><creatorcontrib>Doble, Adam</creatorcontrib><creatorcontrib>Tariq, Luqman</creatorcontrib><creatorcontrib>Aziz, Fayaz</creatorcontrib><creatorcontrib>El Hasnaoui, Abdelkader</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arab Journal of Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noweir, Amr</au><au>Abusamra, Ashraf</au><au>Al Zarooni, Abdelqader</au><au>Binbay, Murat</au><au>Doble, Adam</au><au>Tariq, Luqman</au><au>Aziz, Fayaz</au><au>El Hasnaoui, Abdelkader</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme</atitle><jtitle>Arab Journal of Urology</jtitle><addtitle>Arab J Urol</addtitle><date>2022-01-02</date><risdate>2022</risdate><volume>20</volume><issue>1</issue><spage>14</spage><epage>23</epage><pages>14-23</pages><issn>2090-598X</issn><eissn>2090-598X</eissn><eissn>2090-5998</eissn><abstract>To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster).
The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L).
In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3-15.4%) in Turkey, to 23.76% (95% CI 21.8-25.6%) in Egypt, and 23.79% (95% CI 21.2-26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%;
< 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (
< 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (
< 0.001).
The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>35223105</pmid><doi>10.1080/2090598X.2021.2010451</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2090-598X |
| ispartof | Arab Journal of Urology, 2022-01, Vol.20 (1), p.14-23 |
| issn | 2090-598X 2090-598X 2090-5998 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8881068 |
| source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| title | Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: Results of the SNAPSHOT programme |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T07%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20benign%20prostatic%20hyperplasia%20among%20the%20adult%20general%20population%20of%20five%20Middle%20Eastern%20Countries:%20Results%20of%20the%20SNAPSHOT%20programme&rft.jtitle=Arab%20Journal%20of%20Urology&rft.au=Noweir,%20Amr&rft.date=2022-01-02&rft.volume=20&rft.issue=1&rft.spage=14&rft.epage=23&rft.pages=14-23&rft.issn=2090-598X&rft.eissn=2090-598X&rft_id=info:doi/10.1080/2090598X.2021.2010451&rft_dat=%3Cpubmed_cross%3E35223105%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35223105&rfr_iscdi=true |